Plasminogen Activator Inhibitor 1 and Methylenetetrahydrofolate Reductase Gene mutations in Iranian Women with Polycystic Ovary Syndrome

被引:39
|
作者
Idali, Farah [2 ]
Zareii, Said
Mohammad-Zadeh, Afsane [2 ,3 ]
Reihany-Sabet, Fakhreddin [3 ]
Akbarzadeh-Pasha, Zoreh [3 ]
Khorram-Khorshid, Hamid-Reza [2 ]
Zarnani, Amir-Hassan [4 ]
Jeddi-Tehrani, Mahmood [1 ]
机构
[1] Shahid Beheshti Univ, ACECR, Avicenna Res Inst, Monoclonal Antibody Res Ctr, Tehran, Iran
[2] Avicenna Res Inst, Reprod Immunol Res Ctr, Tehran, Iran
[3] Avicenna Res Inst, Avicenna Infertil Clin, Tehran, Iran
[4] Avicenna Res Inst, Nanobiotechnol Res Ctr, Tehran, Iran
关键词
Methylenetetrahydrofolate reductase; PAI-1; polycystic ovary syndrome; recurrent pregnancy loss; RECURRENT PREGNANCY LOSS; CORONARY-HEART-DISEASE; HOMOCYSTEINE LEVELS; 4G5G POLYMORPHISM; VASCULAR-DISEASE; RISK-FACTORS; PAI-1; GENE; PREVALENCE; MTHFR; C677T;
D O I
10.1111/aji.12002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Problem Mutations in genes related to thrombophilia and hypofibrinolysis have been associated with recurrent pregnancy loss (RPL) and polycystic ovary syndrome (PCOS). Methods Using PCR-RFLP, we investigated the frequencies of MTHFR (A1298C and C677T) as well as PAI-1 (-675 4G/5G) gene polymorphisms in 177 RPL and 100 control women. RPL women were stratified into 38 women with PCOS (RPL-PCOS), 33 with ovarian PCO (RPL-ovarian PCO), and 106 without PCOS (RPL). Results RPL, RPL-PCOS, and RPL-ovarian PCO groups showed significantly higher frequencies of MTHFR A1298C (P<0.001) and PAI-1 4G/5G (P<0.001) mutations than the controls. No significant differences were found between the RPL groups. The respective odds ratios (OR) for bearing MTHFR (A1298C, C677T) and PAI-1 (4G/5G) gene mutations were 33.9-, 2.2-, and 5.2-fold higher in RPL, 66.3-, 6.7-, and 2.8-fold higher in RPL-PCOS, and 27.3-, 1.9-, and 3.9-fold higher in RPL-ovarian PCO women than those in controls. Conclusion Our results showed the significance of MTHFR A1298C and PAI-1 4G/5G mutations in Iranian women suffering from RPL with and without PCOS.
引用
收藏
页码:400 / 407
页数:8
相关论文
共 50 条
  • [1] Plasminogen activator and plasma activator inhibitor-1 in young women with polycystic ovary syndrome
    Lin, Sun
    Guan Yongmei
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2008, 100 (03) : 285 - 286
  • [2] A polymorphism of the plasminogen activator inhibitor-1 gene promoter and the polycystic ovary syndrome
    Walch, K
    Grimm, C
    Huber, JC
    Nagele, F
    Kolbus, A
    Hefler, LA
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2005, 123 (01) : 77 - 81
  • [3] Plasminogen activator inhibitor 1: Associations with metabolic and proinflammatory factor in polycystic ovary syndrome women
    Sales, M. F.
    Soter, M. O.
    Candido, A. L.
    Fernandes, A. P.
    Sousa, M. O.
    Ferreira, A. C. S.
    Dusse, L. M. S.
    Ferreira, C. N.
    Gomes, K. B.
    [J]. THROMBOSIS RESEARCH, 2013, 131 : S88 - S88
  • [4] The plasminogen activator system in women with polycystic ovary syndrome
    Atiomo, WU
    Bates, SA
    Condon, JE
    Shaw, S
    West, JH
    Prentice, AG
    [J]. FERTILITY AND STERILITY, 1998, 69 (02) : 236 - 241
  • [5] Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome
    Lindholm, Asa
    Bixo, Marie
    Eliasson, Mats
    Hudecova, Miriam
    Arnadottir, Ragnheidur
    Holte, Jan
    Poromaa, Inger Sundstrom
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2010, 26 (10) : 743 - 748
  • [6] Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?
    Orio, F
    Palomba, S
    Cascella, T
    Tauchmanovà, L
    Nardo, LG
    Di Biase, S
    Labella, D
    Russo, T
    Savastano, S
    Tolino, A
    Zullo, F
    Colao, A
    Lombardi, G
    [J]. REPRODUCTIVE BIOMEDICINE ONLINE, 2004, 9 (05) : 505 - 510
  • [7] Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome
    Glueck, CJ
    Sieve, L
    Zhu, BH
    Wang, P
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (03): : 345 - 352
  • [8] Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome
    Ekaterini Koiou
    Konstantinos Tziomalos
    Ilias Katsikis
    Dimitrios Delkos
    Elena A. Tsourdi
    Dimitrios Panidis
    [J]. Hormones, 2013, 12 : 559 - 566
  • [9] Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome
    Koiou, Ekaterini
    Tziomalos, Konstantinos
    Katsikis, Ilias
    Delkos, Dimitrios
    Tsourdi, Elena A.
    Panidis, Dimitrios
    [J]. HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2013, 12 (04): : 559 - 566
  • [10] The plasminogen activator system in young and lean women with polycystic ovary syndrome
    Tarkun, I
    Cantürk, Z
    Arslan, BÇ
    Türemen, E
    Tarkun, P
    [J]. ENDOCRINE JOURNAL, 2004, 51 (05) : 467 - 472